and has revolutionised the management of CS but a small number of patients do not respond to this treatment and in others refractory disease may develop. In these cases some alternative treatment is required. Meta-iodobenzylguanidine (MIBG) has been used in the investigation and treatment of phaeochromocytoma and although mentioned This letter was shown to the authors who responded as follows:
Sir, We agree with many of the comments by Jolobe. Our paper was an attempt to provide a summary of contemporary knowledge, derived mostly from major clinical trials and epidemiological data, which can be applied in the management of congestive heart failure, a condition that is becoming increasingly common as the population in our countries ages. Clinicians can only use guidelines as a distillation of the knowledge available with which to guide practice but must make unique judgements in providing the individual patient with effective and safe therapy. We too have faced the frail, hypotensive patient with a severely impaired left ventricular function who cannot tolerate even a small dose of an ACE inhibitor and in whom we have to consider the use of other vasodilators. In hypokalaemic patients requiring large doses of diuretics, the combination of potassium-sparing diuretics such as spironalactone with an ACE inhibitor can be useful and can replace the large doses of otherwise necessary potassium supplements, but in this case it is only sensible that serum potassium levels be monitored regularly to avoid the danger of hyperkalaemia. We are aware of the need for additional therapy in special groups of patients as mentioned by Jolobe, but we decided to refrain from expressing opions about therapies which appear physiologically sound but on which there are no definitive trial data. We also agree that the diagnostic and therapeutic options are far from complete, and there are many more research opportunities to be explored. KOON 
